AAIC abstract submission
Research only
All of alz.org
ALZ.ORG Research Center Alzheimer's Association International Conference ISTAART Journal Grants TrialMatch Press Donate Contact


Presentation types
Themes, topics and subtopics
Frequently asked questions

Presentation types

Authors may select from three presentation formats when submitting an abstract for AAIC, including:

AAIC Poster Presentation (individual)

AAIC Oral Session (individual)

AAIC Featured Research Session (FRS)

Themes, topics and subtopics

Selection of a theme, topic and subtopic for the abstract allows submitters to "self-identify" the area in which the abstract best fits. This identification is the first step in sorting abstracts for the Scientific Program Committee, who will take this identification into consideration and will group related abstracts with similar topics into the same session. Selection of a primary theme, topic and subtopic is required.

AAIC Abstract Submission Themes




Basic and Translational Science

Development of New Models and Analysis Methods

  • α-synuclein
  • Amyloid/Abeta
  • Behavioral models
  • Neuroinflammation
  • Novel assays and technologies
  • Screening studies/platforms
  • Seeding and spreading of proteinopathies
  • Tau
  • TDP-43
  • Validation of pre-clinical methods



  • Blood-borne markers of CNS disease
  • Endophenotypes
  • Epigenetics
  • Genetic factors of Alzheimer’s disease
  • Genetic factors of non-Alzheimer’s tauopathies
  • Genetics of cognitive aging

Molecular and Cell Biology

  • α-synuclein
  • β-amyloidosis
  • APP/Abeta/Amyloid
  • Axonal transport
  • Calcium homeostasis
  • Cell cycle disruption
  • Endosomal-lysosomal dysfunction
  • Enzyme activities
  • Mitochondrial function/energetics
  • Neurodegeneration and neuroprotection
  • Neurofibrillary degeneration
  • Neuroinflammation
  • Neuronal cell death mechanisms (i.e. apoptosis)
  • Neurotrophin mechanisms
  • Others
  • Oxidative stress
  • Presenilins
  • Protein clearance/recycling
  • Receptors
  • Signal transduction
  • Stem Cells, IPS cells
  • Synaptic disruption
  • Tau
  • TDP-43
  • Vascular factors

Protein-Protein interactions




Diagnosis and Prognosis

Biomarkers (non-neuroimaging)

  • Differential diagnosis
  • Longitudinal change over time
  • Method development and/or quality control
  • Multi-modal comparisons
  • Novel biomarkers
  • Plasma/serum/urine biomarkers
  • Prognostic utility
  • Use in clinical trial design and evaluation


Clinical (neuropsychiatry and behavioral neurology)

  • Assessment/measurement of neuropsychiatric/behavioral and psychological symptoms
  • Behavioral neurology
  • Dementia
  • Mild cognitive impairment/early symptomatic disease
  • Neuropsychiatry
  • Non-pharmacologic interventions
  • Presymptomatic disease/prodromal disease/prodromal states
  • Treatment development and clinical trials


  • Animal imaging
  • Differential diagnosis
  • Evaluating treatments
  • Imaging and genetics
  • Multi-modal comparisons
  • New imaging methods
  • Normal brain aging
  • Optimal neuroimaging measures for early detection
  • Optimal neuroimaging measures for tracking disease progression


  • Alpha-synuclein
  • Amyloid
  • Clinico-pathologic correlations
  • Etiopathogenesis--links to brain disease
  • Imaging-pathologic correlations
  • Novel methods
  • Other
  • Proteinopathies
  • Selective vulnerability
  • Tau
  • Topography of pathology
  • Vascular


  • Computerized neuropsychological assessment
  • Early detection of cognitive decline with neuropsychological tests
  • Multicultural issues in assessment of dementia
  • Neuropsychological correlates of physiologic markers of cognitive decline/dementia
  • Neuropsychological profiles of dementia: Valid biomarkers?
  • Normal cognitive aging




Public Health and Psychosocial

Dementia Care Practice

  • Innovative programs and practices
  • Leadership and staff development
  • Policy and systems change
  • Program evaluation and care interventions



  • Epidemiology of MCI and dementia
  • Epidemiology of risk factors for dementia


Health Economics and Policy

  • Cost of care
  • Policy and plans
  • Services


Prevention (non-pharmacological)

  • No subtopics


Psychosocial and Environmental

  • Assessment and care planning
  • Behavioral interventions
  • Environmental design and technology
  • Family/lay caregiving
  • Instrument development, program evaluation and translation
  • Living with dementia and quality of life
  • Long-term and community care
  • Therapeutic strategies and interventions






  • Ethical issues
  • Human trials: Cognitive enhancement
  • Human trials: Nutraceuticals and non-pharmacological interventions
  • Human trials: Other behavioral symptoms
  • Human trials: Anti-amyloid
  • Human trials: Anti-tau
  • Human trials: Inflammation
  • Human trials: Other
  • Novel outcomes measures
  • Prevention (clinical)
  • Trial design



  • Lead optimization studies
  • Natural products and nutraceuticals
  • Non-pharmacological interventions
  • Novel screening strategies
  • Target identification and validation studies: Amyloid
  • Target identification and validation studies: Cognitive enhancement and other behavioral symptoms
  • Target identification and validation studies: Inflammation and innate immunity
  • Target identification and validation studies: Mitochondria and neuroprotection
  • Target identification and validation studies: Other
  • Target identification and validation studies: Proteostasis
  • Target identification and validation studies: Tau

Abstract submissions are now open

Submit an abstract today to share your research on a global stage during AAIC 2016. The Scientific Program Committee is now accepting submissions for poster presentations, oral sessions and featured research sessions.

A global forum to advance dementia science • Toronto, Canada • Conference: July 22–28, 2016